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S
urface camouflaging of nanospheres
with poly(ethylene glycol) (PEG) and
block copolymers such as poloxamine
908 [a tetrafunctional polyethylene oxide
(PEO)polypropylene oxide (PPO) ethyl-
enediamine block copolymer] is believed
to circumvent the bodys defenses (notably
against hepatic macrophage, Kupffer cells,
recognition, and clearance) thus conferring
longevity to nanospheres in the blood fol-
lowing intravenous adminstration.13 How-
ever, the macrophage evading property
and circulation times of such engineered
nanoparticles depend on their size, rigidity,
and surface density of the camouflaging
polymers.2,4,5 For example, intravenously in-
jected uncoated and poloxamine 908-
coated model polystyrene nanoparticles of
50200 nm in diameter with PEO chains in
the “mushroom” configuration are prone to
rapid sequestration by Kupffer cells. In con-
trast, polystyrene particles of similar size
ranges but with surface-projected PEO seg-
ments displaying a transitional
“mushroombrush” or “brush” configura-
tion are resistant to rapid Kupffer cell clear-
ance and remain in the blood for prolonged
periods.46 With larger particles (200300
nm) displaying mushroombrush or brush
PEO chains splenic clearance
predominates.7,8 The splenic filtration pro-
cess is a function of particle size and rigid-
ity, since these particles are larger than the
width of interendothelial cell slits at the
walls of splenic venous sinuses (as in the
rat model) and their rigidity prevents them
from squeezing out in to the venous
circulation.7,9 Filtered particles are eventu-
ally taken up by the splenic red-pulp
macrophages presumably as a result of par-
tial displacement of the adsorbed copoly-
mer in the spleen red-pulp. For particles
above 300 nm in size the poloxamine coat-
ing is ineffective (even in brush conforma-
tion) in combating rapid Kupffer cell clear-
ance. This probably indicates that the
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ABSTRACT Nanoparticles with surface projected polyethyleneoxide (PEO) chains in “mushroombrush” and
“brush” configurations display stealth properties in systemic circulation and have numerous applications in site-
specific targeting for controlled drug delivery and release as well as diagnostic imaging. We report on the
“structureactivity” relationship pertaining to surface-immobilized PEO of various configurations on model
nanoparticles, and the initiation of complement cascade, which is the most ancient component of innate human
immunity, and its activation may induce clinically significant adverse reactions in some individuals.
Conformational states of surface-projected PEO chains, arising from the block copolymer poloxamine 908
adsorption, on polystyrene nanoparticles trigger complement activation differently. Alteration of copolymer
architecture on nanospheres from mushroom to brush configuration not only switches complement activation
from C1q-dependent classical to lectin pathway but also reduces the level of generated complement activation
products C4d, Bb, C5a, and SC5b-9. Also, changes in adsorbed polymer configuration trigger alternative pathway
activation differently and through different initiators. Notably, the role for properdin-mediated activation of
alternative pathway was only restricted to particles displaying PEO chains in a transition mushroombrush
configuration. Since nanoparticle-mediated complement activation is of clinical concern, our findings provide a
rational basis for improved surface engineering and design of immunologically safer stealth and targetable
nanosystems with polymers for use in clinical medicine.
KEYWORDS: block copolymers · complement activation · nanomedicine ·
poloxamine 908 · stealth nanoparticles
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dimensions of the stabilizing chains of the copolymer
does not exceed the range of van der Waals attraction
force, thus making particles susceptible to blood op-
sonization processes and hence macrophage recogni-
tion and clearance.
Complement is an ancient component of innate im-
munity that monitors host invaders including man-
made nanoparticles.10,11 It comprises three distinct
pathways (classical, lectin, and alternative), and is func-
tionally composed of over 30 soluble and membrane-
bound proteins, with each responding to a different set
of activators (Figure 1). Complement primes targets (in-
cluding stealth nanosystems)1,2 for immune clearance
through surface opsonization with C3 cleavage prod-
ucts C3b and iC3b, triggers inflammatory reactions, and
may induce tissue damage (e.g., directly by the lytic
C5b-9 complex) and initiate adverse reactions (e.g., indi-
rectly by anaphylatoxins C3a and C5a through their ef-
fect on different blood cells) in some individuals.10,1215
Complement also guides the adaptive immune re-
sponse. There are clinical reports of acute hypersensitiv-
ity reactions to infusion of long circulating regulatory-
approved nanoparticles (e.g., Doxil, a PEGylated
liposome with entrapped doxorubicin) in certain
individuals.1618 These reactions are non-IgE mediated
and often associated with flushing and circulatory/car-
diac disturbances.19 Neuro-psychosmatic and vegeta-
tive responses have further been observed following
Doxil infusion in dogs.19 Recent studies in pigs have
suggested that the cardiopulmonary distress caused
by Doxil and other nanoparticles strongly correlates
with complement activation.20 It is now known that
PEGylated liposomes can trigger complement activa-
tion in the absence of anti-PEG antibodies through both
C1q-dependent classical and alternative pathways.21
The incidence of such adverse responses corresponds
Figure 1. Complement activation pathways. Surface binding of sensing molecules triggers complement through different pathways.
The classical pathway is initiated by the binding of the C1q component of the C1 protein to native or antibody or C-reactive protein-
decorated surfaces. The lectin pathway is typically activated when mannose-binding lectin (MBL) or ficolin interact with surface sugar
molecules (mannose) or some other surface entities. Sequential activation of other complement proteins for each pathway is shown;
however, activation of both pathways leads to the assembly of C3 convertase C4b2a. Direct cleavage of C3 by MBL-associated serine
proteases can also occur. The alternative pathway is a self-amplification loop driven by C3bBb convertase. Alternative pathway turn-
over can occur secondary to classical and lectin pathway activation or be initiated directly by foreign surfaces. The later occurs through
low level spontaneous C3 “tickover” generating nascent C3b, which is susceptible to nucleophilic attack by OH or NH2 groups ex-
posed on nanoparticle surfaces. Direct C3 binding may also trigger an alternative pathway. The terminal step of complement path-
ways generates C5 convertases that through sequential activation of complement proteins C5 to C9 assemble the terminal C5b-9
complement membrane-attack complex.
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to approximately 80% of all immune-mediated hyper-
sensitivity reactions; this translates to the occurrence of
at least 400 000 severe reactions with 20 000 fatalities
every year in the United States only.22 Such outcomes
can therefore complicate the development phase of
new nanomedicines and other potential multifunction-
al/composite nanoparticles for clinical applications. In
this respect, previous attempts have rarely focused in
assessing the role of surface projected polymers on
pathways and mechanisms of complement activation.
These issues are also important in terms of optimizing
nanoparticulate drug carrier stability (particularly for
vesicular systems, since complement activation can
damage the liposomal bilayer resulting in premature
drug leakage) and pharmacokinetics in the blood,
as well as for translation in to surface engineering
of other nanomaterials of different morphology and
structure (e.g., carbon nanotubes) for improving
their biocompatibility.23
Since block copolymers of poloxamer and poloxam-
ine series are widely used for nanoparticle surface
engineering,1,4,69,2427 we have investigated and com-
pared complement activation in human serum by
poloxamine 908-coated nanoparticles of 230 nm with
Figure 2. Physicochemical characteristics of uncoated and poloxamine 908-conditioned polystyrene nanoparticles. (a)
Poloxamine 908 structure, (b) a single curve poloxamine 908 adsorption isotherm with a bimodal feature, (c) physicochem-
ical characteristics of poloxamine-coated nanoparticles from selected regions of the adsorption isotherm, and (d) scanning
electron micrographs of representative nanoparticles on a graphite base; bar  500 nm.
A
RTIC
LE
www.acsnano.org VOL. 4 ▪ NO. 11 ▪ 6629–6638 ▪ 2010 6631
surface-projected PEO chains displaying mushroom,
mushroombrush, and brush configurations. The phys-
icochemical properties of poloxamine-coated particles
are well characterized and established;5 therefore they
serve as an excellent working platform for assessing
structureactivity relationships to aid in the under-
standing of key mechanistic issues pertaining to
complement and innate immunity. We now demon-
strate that poloxamine 908-coated nanospheres incite
complement activation in human serum regardless of
PEO chain configuration, but remarkably alteration of
copolymer architecture on nanospheres from mush-
room to mushroombrush configuration switches acti-
vation from the classical to the lectin pathway. Also,
variation in adsorbed polymer configuration triggers al-
ternative pathway activation differently and the mecha-
nistic aspects are discussed. Since nanoparticle-
mediated complement activation is of significant clini-
cal concern, our findings provide a rational basis for pre-
cision surface engineering and design of immunologi-
cally safer stealth and target-specific nanosystems with
polymers for application in clinical medicine.
RESULTS AND DISCUSSION
Nanoparticle Characteristics. In accordance with our pre-
vious study5 the results in Figure 2b demonstrate a bi-
modal pattern for poloxamine 908 adsorption onto
the surface of near monodispersed polystyrene nano-
particles (230 nm). This feature reflects dynamic
changes in the arrangement of surface projected poly-
ethylene oxide (PEO) chains; a flat or mushroom-like
conformation at the first plateau region of the isotherm,
followed by a transition into a brush-like conforma-
tion, as previously assessed by us using a combination
of laser light scattering, viscosity measurements, and
nanorheological studies with atomic force microscopy
(height and phase lag measurements in tapping
mode).5 For structureactivity studies in relation to
nanosphere surface properties and initiation of comple-
ment activation we explicitly focused on representa-
tive nanospheres from each plateau region of the ad-
sorption isotherm (B and D), and a population between
the plateau regions (C), and compared them with un-
coated nanospheres (A), Figure 2c. Physicochemical
characteristics of the selected nanospheres [poloxam-
ine adsorbed layer thickness (), poloxamine surface
density, zeta potential (), and apparent viscosity] are
presented in Figure 2c; and the results are comparable
with our previous study.5 SEM micrographs further
demonstrate the effect of polymer conformation on
the packing arrangement of nanoparticles (Figure 2c).
Uncoated nanospheres aggregate in an unstructured
way, but form regular arrangements when coated with
poloxamine 908 to the level of the first plateau of the
adsorption isotherm, where the available surface area is
in the region of 45 nm2/poloxamine molecule. For types
C and D nanoparticles the coating arrangement trans-
lates to a surface area of 30 and 15 nm2/poloxamine
molecule, respectively, where subsequent layers form
a three-dimensional close-packed array (as in type D).
This presumably arises from the repulsive forces of
ether oxygen atoms of projecting PEO chains.
Biodistribution Studies. The results in Figure 3 demon-
strate differences in blood clearance profile and organ
distribution of engineered nanopsheres, which are in
line with the presumed surface-projected PEO configu-
rational states. Accordingly, nanospheres A and B are
rapidly cleared by the hepatic macrophages, whereas
Figure 3. Blood clearance and organ distribution of intravenously injected poloxamine-coated nanospheres. Uncoated nanospheres
are designated as A; designations B, C, and D refer to poloxamine-coated nanospheres from the 1st plateau, midway, and top plateau
of the adsorption isotherm, respectively.
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nanospheres C and D exhibit stealth properties but are
eventually filtered by the spleen.
Complement Activation by Nanoparticles.Uncoated nano-
spheres dramatically elevated serum levels of fluid-
phase complement activation products C4d (a degrada-
tion product of C4, mediated by complement control
protein C4bp and factor I, and an established marker of
both classical and lectin pathways),21,28 Bb (an estab-
lished marker of the alternative pathway turnover re-
sulting from Factor B cleavage),21,28 C5a (the most po-
tent complement anaphylatoxin), and the nonlytic
SC5b-9 (the vitronectin or S protein bound form of
C5b-9, and a marker of terminal complement path-
way)21 above background (Figure 4). Poloxamine coat-
ing did not abrogate complement activation fully.
Complement activation occurred with both nano-
spheres B (displaying mushroom PEO conformation)
and C (with a transitional mushroombrush configura-
tion), but dramatically reduced with type D entities,
where the surface projected PEO chains predominantly
assume brush-like arrangement.
The Role of Classical and Lectin Pathways of Complement. Sur-
face binding of C1q component of the complement
protein C1 complex triggers activation of the classical
pathway of complement.10,21 This mode of activation
generates the C3 convertase C4b2a through sequen-
tial activation of C4 and C2 proteins involving serine
proteases C1r and C1s (Figure 1). To distinguish be-
tween nanoparticle-mediated activation of classical and
lectin pathways of complement, serum was immu-
nochemically depleted from C1q, and C4d levels were
monitored in C1q-depleted serum. This distinguishes
between the classical and lectin pathways, since the lat-
ter is activated through surface binding of mannose
lectin-binding protein (MBL) and/or ficolins. The bind-
ing of MBL and/or ficolins to nanoparticles in turn in-
duces activation of the MBL-associated serine proteases
(MASPs), notably MASP-2. This subsequently cleaves
the C4 protein resulting in ultimate formation of C4b2a
convertase, which structurally is identical to the classi-
cal pathway C3 convertase.2830
Uncoated nanospheres did not affect C4d levels in
C1q-depleted serum, but these increased dramatically
when physiological concentrations of C1q was added
(Table 1). This attests to the involvement of C1q-
mediated classical pathway activation. Similar results
were obtained with type B nanospheres, but not with
nanospheres C and Dwhere activation is predominantly
via lectin pathway, since the nanosphere challenge dra-
matically elevates C4d levels in C1q-depleted serum
Figure 4. Nanosphere-mediated elevation of complement activation products in human serum. The horizontal lines (ad)
denote background levels of activation products.
TABLE 1. Nanoparticle-Mediated C4d Rises in C1q-Depleted Human Serum
C4d (g/mL serum)
nanospheres C1q treatment C1q treatment nonspecific Ab treatment anti-MASP2 Ab treatment
none 6.2 0.8 7.4 0.9 7.3 1.0 7.5 0.4
A (uncoated) 6.8 0.6 22.6 1.1 7.1 0.4 8.3 0.5
B 5.6 0.9 18.9 0.7 6.1 0.9 8.8 1.4
C 15.2 1.2 18.2 0.8 17.5 1.6 8.8 1.9
D 11.8 0.6 12.9 0.8 12.8 1.1 6.9 1.8
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(Table 1). This was further confirmed by blocking the ac-
tivity of the lectin pathway convertase MASP-2 by an
anti-MASP-2 monoclonal antibody (Table 1).
With type B nanospheres, incubations contain 5.4
g of surface-bound poloxamine in a final volume of
40 L serum; this translates to an equivalent of 135 g
of free poloxamine/mL serum, which is below its cmc
value (700 g/mL) determined by both static light scat-
tering and fluorescence anisotropy. Free poloxamine
at concentrations above 75 g/mL serum dramatically
elevate serum C4d levels (Figure 5a); this is exclusively
lectin pathway driven, since C4d elevation is blocked
by anti MASP-2 antibodies (Figure 5b). If surface-
adsorbed poloxamine molecules were displaced by se-
rum proteins, then poloxamine molecules should have
further triggered complement in C1q-depleted serum
via lectin pathway. Therefore, C1q-dependent comple-
ment activation by nanosphere B is a true reflection of
surface property, where a mushroom-like PEO configu-
ration neither triggers lectin pathway nor blocks C1q
binding to the nanosphere surface by steric hindrance.
This further reflects the role of PEO conformation in dif-
ferential binding of key serum/plasma protein, at least
in relation to complement components.
Lectin pathway activation by nanospheres C and D
is remarkable (Table 1), since surface-projected PEO
chains were expected to dramatically suppress surface
opsonization events.2 It is unlikely that the lectin path-
way is triggered by displaced (free) poloxamine mol-
ecules. Earlier work with radio-labeled poloxamine 908-
coated (at plateau region of the adsorption isotherm)
polystyrene nanoparticles (250 nm) demonstrated that
not more than 10% of poloxamine molecules are re-
leased after 3 h incubation in serum.31 With nano-
spheres C and D, this translates to less than 25 and 40
g poloxamine/mL serum, respectively, which is far be-
low the minimum free poloxamine concentration nec-
essary to trigger complement via the lectin pathway
(Figure 5a). Therefore, nanosphere-mediated lectin
pathway activation is likely due to interaction between
MBL and/or ficolin with projected PEO chains, resulting
in activation of their associated serine protease zy-
mogen MASP-2. Indeed, nanosphere-mediated C4d el-
evation in serum is blocked in the presence of
N-acetylglucosamine, a substrate for both MBL and fi-
colin (not shown).28 It is interesting to note that there
are structural similarities between the terminal PEO
chains of poloxamine and a region of D-mannose that
Figure 5. Poloxamine 908-mediated complement activation in normal human serum (a) and poloxamine-mediated C4d el-
evation in C1q-depleted human serum. In panel b poloxamine concentration was 100 g/mL serum. C4d elevation is abro-
gated in the presence of anti MASP-2 antibodies indicating a role for the lectin pathway in C4 cleavage. A nonspecific IgGwas
included in the control experiment. The white line indicates the background level of serum C4d in the presence of nonspe-
cific antibody. Poloxamine samples may contain impurities introduced during synthesis and may also contain small amounts
of butylated hydroxytoluene to prevent degradation. Earlier we demonstrated that such impurities and the presence of
antioxidants have no effect on complement activation.16 Complement activation by poloxamer and poloxamine is an intrin-
sic property of these macromolecules and is independent of the degree of sample polydispersity.16
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could trigger lectin pathway activation at a certain sur-
face density.22
Increasing surface density of poloxamine (as in
nanosphere D) significantly reduces C4d and SC5b-9
generation compared with type C nanospheres, but
C4d elevation is still through the lectin pathway (Fig-
ure 4). Therefore, denser surface PEO brushes (with de-
creased mobility)32 may sterically minimize MBL/ficolin-
MASP-2 binding to PEO backbone or to surface
accumulated mannosylated glycoproteins, such as vari-
ous apolipoproteins.25
The Role of Alternative Pathway. The alternative path-
way of complement is stimulated by the spontaneous
cleavage of the thioester bond in C3 (“C3-tickover”) or
when the internal thioester bond in the -chain of na-
scent C3b undergoes nucleophilic attack in the pres-
ence of structures rich in nucleophilic groups (e.g.,
hydroxyl-rich surfaces).10,28,33 Nanosphere-mediated el-
evation of alternative pathway turnover, as evident
from Bb rises above background13 (Figure 4b), is either
secondary to classical and lectin pathway activation
(amplification loop) or is initiated independently (e.g.,
C3 tickover and nascent C3b binding).10 Both routes are
operative with all types of nanospheres, with the excep-
tion of type D, since nanosphere-mediated Bb eleva-
tion is reduced by approximately 30% in the presence
of EGTA/Mg2(activation of classical and lectin path-
ways are calcium-dependent)21,22 (Figure 6a). With type
D nanospheres complement activation is exclusively
through the amplification loop since no Bb elevation
above background level was detected in the presence
of EGTA/Mg2, Figure 6a. Interestingly, type C particles
were able to increase alternative pathway turnover
through interaction with properdin (a positive regula-
tor as well as a recently identified initiator of alternative
pathway)34,35 as demonstrated in reduction of Bb levels
in the presence of antiproperdin antibodies (Figure 6b).
This is presumably due to noncovalent binding of
properdin to poloxamine chains, thereby recruiting
C3b and allowing for alternative pathway convertase
build-up. Therefore, for the first time we have demon-
strated that poloxamine surface configuration affects al-
ternative pathway activation through different
processes.
CONCLUSION
We have demonstrated the importance of configu-
rational/mobility of surface projected PEO chains in
modulation of complement activation with a spectrum
of model nanoparticles that exhibit different pharmaco-
kinetic profiles. Although stealth properties, and hence
long circulatory profiles, can be achieved by partial
poloxamine surface coverage, immunologically it is nec-
essary to maximize coating. This dramatically reduces
complement activation, presumably due to decrease in
PEO chain mobility,1,32 and the risk of adverse infusion
reactions.1,14,23 In sensitive individuals, rapid production
of complement anaphylatoxins (C3a and C5a) initiates
the release of a wide spectrum of secondary mediators
that subsequently triggers adverse effects. To this end,
Figure 6. Nanosphere-mediated triggering of Bb elevation in the presence of EGTA/Mg2(a) and the role of properdin in
nanosphere-mediated Bb elevation in C1q-depleted human serum with functional lectin pathway (b). In panel b the effect
was exclusive with type C nanospheres. The white line indicates background Bb level in serum in the presence of the nonspe-
cific antibody.
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structureactivity relationships between complement
activation and conformational states of immobilized co-
polymers must be considered for rational design of im-
munologically safe stealth nanoparticles. Particular em-
phasis must be placed to suppress or prevent
complement activation through the alternative path-
way, which presents a unique role in the complement
activation cascade. Since alternative pathway is acti-
vated by its own product (C3b), it functions as a posi-
tive feedback loop, producing a vigorous local re-
sponse. Our observation that properdin binding to
type C nanospheres can also trigger alternative path-
ways is of concern. Properdin is synthesized by blood
monocytes, CD4 and CD8 blood T cells, and neutro-
phils.36 In neutrophils, properdin is stored in secondary
granules and can be released following stimulation with
secondary mediators.37 In the blood, rapid properdin re-
lease, and following binding to surfaces such as type C
nanoparticles, may further aid C5a generation through
alternative pathway convertase assembly and inflict fur-
ther damage. This may further disrupt the delicate bal-
ance between complement regulation and comple-
ment activation. Accordingly, assessment of
complement activation pathways by the described
nanospheres in whole blood would be of immense in-
terest and should be investigated. Furthermore, future
efforts should concentrate in assessing the role of im-
mobilized polymer conformation on particles of 100 nm
or below in size since curvature cannot only control
polymer mobility but also modulate surface deposition
of sensing molecules (e.g., antibodies, C1q, etc.) that
trigger complement.2 In addition, smaller sizes (30 nm
and below) in conjugation with surface dynamic events
arising from adsorbed or conjugated polymers may re-
strict surface assembly of complement convertases,
which are of similar size ranges.2 Our findings may also
be relevant to mechanistic understanding of comple-
ment activation by biodegradable polymeric stealth
nanoparticles such as PEGylated polyalkylcyanoacry-
late nanospheres and PEGylated poly(D,L,lactide) nano-
capsules, and could lead to design of safer polymeric
stealth systems for clinical applications. Similar to
poloxamine 908-coated nanoparticles, these entities ac-
tivate complement regardless of surface PEG chain
length and density, but the extent of complement acti-
vation decreases with longer PEG chains.38,39 However,
mechanistic aspects still remain to be resolved.
Previously we have demonstrated that splenotropic
poloxamine-coated nanoparticles following splenic fil-
tration are internalized by splenic red-pulp macrophag-
es.8 Although complement fixation and opsonization
by C3b and iC3b could facilitate nanoparticle uptake by
these macrophages, recent studies with PEGylated lipo-
somes, which also fix complement opsonic proteins,
have shown that the steric barrier of projected PEG in-
terferes with the binding of the opsonic protein to the
macrophage complement receptor.21 This process is
most likely to occur with nanospheres C and D, other-
wise rapid hepatic sequestration would have occurred.
Therefore, alternative splenic red-pulp macrophage up-
take mechanisms are in operation with regard to clear-
ance of filtered poloxamine-coated nanoparticles and
are worthy of future investigation.
MATERIALS AND METHODS
Poloxamine Characterization and Adsorption Isotherm Studies. Polox-
amine 908 was a kind gift of BASF Aktiengesellschaft (Ludwig-
shafen, Germany), used without further modification, and char-
acterized as before (Mw  22455; Mn  13220; Mz  28190).5
Endotoxin-free poloxamine 908 solutions were prepared in 10
mM McIlvaine buffer (pH 7.2). The critical micelle concentration
(cmc) of poloxamine 908 was determined by static light scatter-
ing. Measurements were performed at 37 °C at a 90° angle using
a BI-SM200 Brookhaven instrument, equipped with a 100 mW
HeNe laser with a wavelength of 632.8 nm. The sample cell was
embedded in a refractive index matched bath. The static light
scattering from poloxamine 908 in the concentration range from
0.0164 mg/mL was measured. Each measurement was done
in triplicate. The cmc was further measured by fluorescence
anisotropy on a Hitachi F7000 fluorescence spectrophotometer
giving a comparable value.
Polystyrene nanoparticles (2.5% w/v), 230 0.5 nm in diam-
eter, manufactured by Polysciences Inc. (USA), were purchased
from Park Scientific (Northampton, UK). Poloxamine-coated par-
ticles were prepared in triplicate by adding 1.25 mg of polysty-
rene nanoparticles (endotoxin free) to poloxamine solutions
ranging from 0 to 400 g/mL poloxamine (00.0178 mM) in a
total volume of 1.0 mL in Eppendorf tubes. All tubes were shaken
gently (100 rpm) for 24 h at 25 °C in a water bath. The suspen-
sions were then centrifuged for 40 min at 16000g. No polysty-
rene particles were lost in supernatants as monitored by light
scattering during the centrifugation steps. Poloxamine concen-
tration was determined by a highly sensitive biphasic colorimet-
ric assay for the resulting supernatants using a standard curve
run concurrently with the adsorption experiment (control tubes
without any polystyrene particles but containing the same con-
centrations of poloxamine as in adsorption isotherm).40 Briefly,
for the colorimetric assay, aliquots (in a total volume of 0.5 mL)
of standard poloxamine solutions (in McIlvaine buffer, pH 7.2) or
supernatants from the adsorption isotherm were added to
Eppendorf tubes containing 0.5 mL of chloroform and 0.5 mL of
reagent solution (400 mM ammonium thiocyanate and 100 mM
anhydrous ferric chloride). The system was then mixed vigor-
ously for 20 min at room temperature to attain equilibrium, fol-
lowed by centrifugation (3 min) using a microfuge at 16000g.
The lower chloroform layer was extracted, transferred to a quartz
cuvette with 1 cm path length, and covered with a small vol-
ume of the reagent solution. The absorbance was measured at
510 nm using a spectrophotometer.
Particle Size and Electrophoretic Mobility. The hydrodynamic ra-
dius and the electrophoretic mobility of particles were deter-
mined by photon correlation spectroscopy (PCS) and laser Dop-
pler electrophoresis, respectively, in 10 mM McIlvaine buffer, pH
7.2, at 25 °C using a Zetasizer 3000 system (Malvern Instru-
ments, UK) as described previously.5,26 PCSmeasurements (based
on CONTIN analysis) were determined at a wavelength of 633
nm, scattering angle of 90°, dispersant viscosity of 0.89 cP, and
refractive index of 1.35, respectively. For electrophoretic mobil-
ity measurement conditions were as follows: dielectric constant,
78.3; current, 1.4 mA; fluid refractive index of 1.35; cell field of
29.3 V/cm; viscosity of 0.89 cP; and conductivity of 0.7 mS/cm.
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Apparent Viscosity Measurements. The viscosity of nanoparticle
suspensions (volume fraction 	  0.18), was measured at 25 
0.1 °C using a Thermo Haake RheoStress 1 rheometer (Gebru¨der
HAAKE GmbH, Germany).5 A C30 coneplate sensor system
with 1° angle and a gap of 0.054 mm was used. Poloxamine-
coated nanoparticles were free from unbound poloxamine mol-
ecules. The viscosity (apparent) was obtained from the slope of
linear part (from 8 to 16 s1) of the shear strain versus shear rate
plot. An oscillation test was also performed with nanoparticle
suspensions at a constant frequency of 1 Hz and strain of
0.0520. Each test was repeated three times. Data analysis was
carried out with the Thermo Haake software RheoWin Pro.
Serum Characterization and Assays of in Vitro Complement Activation.To
measure complement activation in vitro, we determined
nanoparticles/polymer-induced rise of human serum comple-
ment activation product C4d, Bb, C5a, and SC5b-9 using respec-
tive Quidels Enzyme-Linked Immunosorbant Assay (ELISA) kits
according to the manufacturers protocols as described
previously.21,22,28 C1q-depleted human serum (immunochemi-
cally depleted of C1q) was obtained from Quidel. The comple-
ment hemolytic activity of C1q-depleted serum was restorable
following the addition of pure C1q (180 g/mL) as assessed by
the hemolytic test using sheep erythrocytes sensitized with rab-
bit antisheep erythrocyte antibody.28 The functional activity of
classical, lectin, and the alternative pathways of complement
were confirmed in all sera with Wielisa-Total Complement Screen
kit prior to functional studies.28
For measurement of complement activation, the reaction
was started by adding 250 g of designated nanoparticles (in
sterile physiological saline) or required quantities of free polox-
amine to undiluted fresh human serum or C1q-depleted serum
(typical nanoparticles or polymer/serum volume, 1:4) in Eppen-
dorf tubes (in triplicate) in a shaking water bath at 37 °C for 30
min. Reactions were terminated by the addition of PBS supple-
mented with 25 mM EDTA. Control serum incubations contained
saline (the same volume as nanoparticles or polymer) for assess-
ing background levels of complement activation products.
Zymosan, aggregated IgG, and mannan were used as positive
control for alternative, classical, and lectin pathways, respec-
tively. The level of the complement activation products was then
measured by the respective ELISA kits and compared with con-
trol incubations in the absence of nanoparticles or polymer. In
some experiments, nanoparticles/polymer-induced complement
activation was monitored following pretreatment of serum with
EGTA/Mg2 (10 mM/2.5 mM), anti-MASP-2 monoclonal antibody
(HyCult Biotechnology, The Netherlands), antiproperdin anti-
body (Quidel), an irrelevant murine IgG antibody (control),
N-acetylglucosamine (25 mM), and D-galactose (25 mM). Con-
trol serum incubations contained the same quantity of the
added compounds, and nanoparticles/polymer was replaced
with the same volume of saline. In all experiments pH was main-
tained between 6.8 and 7.1. To monitor the possible binding of
complement activation products, we incubated nanospheres
with standard samples of activation products. The level of the
standard activation products in the supernatant was then mea-
sured by the respective ELISA test and compared with control in-
cubations in the absence of nanospheres.
For quantification of complement activation products, stan-
dard curves were constructed using the assigned concentration
of each respective standard supplied by the manufacturer and
validated. The slope, intercept, and correlation coefficient of the
derived best-fit line for C4d, Bb, C5a, and SC5b-9 standard curves
were within the manufacturers specified range. The efficacy of
nanoparticles/polymer treatments was established by compari-
son with baseline levels using paired t test, correlations between
two variables were analyzed by linear regression, and differ-
ences between groups (when necessary) were examined using
ANOVA followed by multiple comparisons with Student-
Newmann-keuls test. Similar patterns were observed in all tested
sera; the result of a typical experiment is presented.
Inductively Coupled Plasma Atomic Emission Spectrometry. Since op-
eration of the alternative pathway is maintained or even acceler-
ated by elevated Mg2 levels, we monitored the contents of cal-
cium and magnesium in poloxamine by inductively coupled
plasma atomic emission spectrometry as described in detail else-
where.22 The results confirmed negligible quantities of such cat-
ions (below 10 g/L), thus confirming complement activation via
the alternative pathway is not driven by sample contamination
with Mg2.
Blood Concentration and Organ Distribution of Nanospheres. Radiola-
beled nanospheres (2 
 1011 particles) were injected intrave-
nously into a group of male Wistar rats (n  3) via the tail vain.
Blood was removed at various intervals for determination of
nanosphere concentration. Animals were killed at appropriate
time intervals and distribution of nanoparticles in liver and
spleen was determined. Full experimental details for radiolabel-
ing and administration are presented elsewhere.6,26
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